Vantage logo

Bluebird split looks premature

Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.

Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.

Vantage logo

Key biotech catalysts approach

Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.

Vantage logo

Ash 2019 winners and losers

Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.